The invention, in some aspects, relates to methods for diagnosing cardiovascular disease, and/or detecting cardiovascular disease in a patient, and more particularly to methods of using blood-based biomarkers and their combinations to identify patients at risk of having cardiovascular disease (e.g., coronary atherosclerosis).

The present disclosure provides for a universal lipid quantitative standard (ULQS) comprising a plurality of isotopically labeled lipid standards that can be used with any analytical mass spectrometry techniques known in the art. The ULQS includes at least one isotopically labeled lipid species from one or more of the following lipid classes: i) phospholipids; ii) lysophospholipids; iii) cholesterol esters; iv) triacylglycerols; v) diacylglycerols; vi) ceramides; and vii) sphingomyelins.

The embodiments of the present application, belonging to the technical field of medical test and assay, and provide a preservative for an in vitro diagnostic reagent. The preservative includes a combination of a sulfadoxine solution and a dimethoprim solution, wherein a molar ratio of sulfadoxine in the sulfadoxine solution to dimethoprim in the dimethoprim solution is from 0.002 to 1. The present disclosure also provides use of the preservative for the in vitro diagnostic reagent. The technical solutions according to the embodiments of the present disclosure improve stability of the reagent, do not affect reactions of the reagent, and may be extensively applied.

The present invention relates to the field of diagnostic methods. Specifically, the present invention contemplates a method for diagnosing heart failure in a subject based on determining the amounts of at least three biomarkers. The invention also relates to tools for carrying out the aforementioned methods, such as diagnostic devices.

Compositions, devices, kits and methods are disclosed for assaying triglyceride with a glycerol 3-phosphate oxidase mutant. The glycerol 3-phosphate oxidase mutant has reduced oxidase activity while substantially maintaining, or increasing, its dehydrogenase activity, compared to the wild-type glycerol 3-phosphate oxidase.

A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient.

Provided herein are methods of detecting lipids in humans suspected of having cancer, in particular detecting lipids in samples from a human suspected of having breast or lung cancer.

This disclosure provides a use of biomarker SM(d18:1/24:1(15Z)) in the preparation of a reagent or kit for diagnosing cognitive impairment. This disclosure also provides a method for diagnosing and treating cognitive impairment by detecting the content of biomarkers SM(d18:1/24:1(15Z)) and TG(16:0/18:0/18:4(6Z,9Z,12Z,15Z)), PC(P-16:0/22:4(7Z,10Z,13Z,16Z) or PC(P-18:0/18:4(6Z,9Z,12Z,15Z)) to determine whether the patient has cognitive impairment.

A method for determining a non-anticoagulant interferent in a blood-derived sample of a subject, the method comprising a) determining a value of a coagulation time-related parameter in the sample; b) comparing the value of the coagulation time-related parameter determined in a) to a value of the coagulation time-related parameter determined in at least one reference sample; and c) based on the result of comparison step b), determining the non-anticoagulant interferent in a blood-derived sample of a subject. A method for identifying a blood-derived sample having insufficient quality is further disclosed, the method comprising determining non-anticoagulant interferent(s) according to the aforesaid method.

The present invention relates to a strip for measuring blood lipids. The strip for measuring blood lipids, of the present invention, presses, with an optimal pressure or to an optimal height, a contact surface of a protruding part of a measurement layer disposed between an upper cover and a lower substrate, so as to improve the uniform diffusion of a biological sample, thereby having an effect of increasing measurement result accuracy of the biological sample.